Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland

Haemophilia

Volumn 23, Issue 3, 2017, Pages e240-e243

  Scott, M ^a,d   Nummi, V ^b,c   Lassila, R ^b,c   Xiang, H ^d   Hay, C R M ^a,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d National Haemophilia Database   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTHROPATHY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG HALF LIFE; FINLAND; FOLLOW UP; GENOTYPE; HEMARTHROSIS; HEMOPHILIA B; HUMAN; LETTER; MIDDLE AGED; MISSENSE MUTATION; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; BLEEDING; COMPLICATION; FEMALE; MALE;

ADOLESCENT; ADULT; AGED; FACTOR IX; FEMALE; FINLAND; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 85019574792     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13228     Document Type: Letter

References (10)

1. Roth D, Kessler C, Pasi J, Rup B, Courter S, Tubridy K. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600–6.
2. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313–23.
3. Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880–6.
4. Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Alvarez-Roman M-T, Voigt C, Blackman N, Jacobs I. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016; 127: 1761–9.
5. Morfini M, Dragani A, Paladino E, Radossi P, Di Minno G, Mazzucconi MG, Rossetti G, Barillari G, Napolitano M, Tagariello G. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia 2016; 22: 537–42.
6. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20: 398–406.
7. Kavakli K, Smith L, Kuliczkowski K, Korth-Bradley J, You C, Fuiman J, Zupancic-Salek S, Karim A, Rendo P. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia 2016; 22: 381–8.
8. Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost 2013; 11: 2176–8.
9. Cooley B, Funkhouser W, Monroe D, Ezzell A, Mann D, Lin F, Monahan P, Stafford D. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood 2016; 128: 286–92.
10. Gui T, Lin HF, Jin DY, Hoffman M, Straight DL, Roberts HR, Stafford DW. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153–8.